Kolon Tissuegene Inc.’s TG-C, an allogeneic cell and gene therapy candidate for knee osteoarthritis (OA), missed both co-primary endpoints and all key secondary endpoints in a highly anticipated top-line phase III clinical trial readout.
Tianjin Tianyao Pharmaceuticals Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of systemic inflammatory response syndrome (SIRS), autoimmune disease, lung and kidney injury and sepsis.
Shanghai Pharmaceuticals Holding Co. Ltd. has discovered cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists found to be potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
